Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: while there's sequential revenue growth and positive developments in sectors like aerospace and defense, the overall year-over-year revenue declined by 9%. The company improved its EBITDA and reduced operating expenses, but gross margins were negatively impacted by a less favorable product mix. The Q&A revealed cautious guidance and some uncertainty, especially around consumer segments. Given these factors, the stock price is likely to remain stable with minor fluctuations, resulting in a neutral sentiment.
Consolidated Revenue (Q4 2025) $106.3 million, an increase of 3% year-over-year (adjusting for Geomagic). When further adjusting for the regenerative medicine adjustment impacting the prior year quarter, consolidated revenue declined 5%. The year-over-year decrease was primarily driven by softness in industrial printer and materials demand, partially offset by double-digit growth across priority markets, including PHS and aerospace and defense.
Sequential Revenue Growth (Q4 2025) 16% sequential increase from Q3 2025, driven by growth in new printer system sales and increased materials consumption.
Industrial Solutions Revenue (Q4 2025) $55.8 million, a 15% sequential increase. Growth driven by continued strength in aerospace and defense and higher new printer sales within consumer end markets, including increasing demand for the new MJP printer for jewelry applications.
Healthcare Solutions Revenue (Q4 2025) $50.5 million, an 18% sequential increase. Growth driven by strengthening dental material sales and continued positive performance of the PHS business.
Full Year 2025 Consolidated Revenue $387 million, a 7% year-over-year decline (adjusting for Geomagic) or 9% decline (adjusting for both Geomagic and the prior year regenerative medicine adjustment). Decline attributed to macroeconomic headwinds impacting customer spending.
Non-GAAP Gross Margin (Q4 2025) 31%, up 3% when adjusting for Geomagic, but down 2% when adjusting for both Geomagic and Regenerative Medicine. Decline attributed to lower sales volume and less favorable product mix.
Non-GAAP Operating Expenses (Q4 2025) $43 million, down 23% or $13 million from the prior year period (adjusting for Geomagic).
Full Year 2025 Non-GAAP Operating Expenses $196 million, a 19% or $46 million reduction year-over-year (adjusting for Geomagic).
Adjusted EBITDA (Q4 2025) Negative $5.3 million, an improvement of $17 million compared to the prior year (adjusting for Geomagic).
Full Year 2025 Adjusted EBITDA Negative $45.4 million, an improvement of $31 million (adjusting for Geomagic).
Full Year 2025 Non-GAAP Loss Per Share $0.37, an improvement from a loss of $0.62 in the prior year period.
Total Cash (End of Q4 2025) $97.1 million, consisting of $95.6 million in cash and cash equivalents and $1.5 million in restricted cash.
New Product Launches: Introduced the dual laser SLA 750 for motorsports and consumer automotive OEMs, and the MJP 300W Plus wax printer for jewelry manufacturing. Launched the NextDent Jetted Denture platform for dental applications.
Healthcare Innovations: Released the NextDent Jetted Denture platform, praised for comfort and fit. Expanded gum shade options for dentures. FDA clearance for VSP solutions for skeletally mature adolescents.
Aerospace and Defense: Achieved 16% growth in 2025, with expectations of over 20% growth in 2026. Focused on metal parts manufacturing using casting and direct metal printing technologies. Expanded U.S. facility in Littleton, Colorado to meet demand.
Dental Market: Targeting a global market of 180 million denture users. Expanded into New Zealand, Colombia, and Chile, with European clearance expected in summer 2026.
Cost Reduction: Achieved $55 million in annualized savings in 2025, exceeding the $50 million target. Streamlined facilities and optimized organizational capacity.
Revenue Growth: Fourth quarter revenue increased 16% sequentially, driven by new printer system sales and increased materials consumption.
Strategic Focus: Prioritized investments in aerospace, defense, and healthcare markets. Limited exposure to low-end applications to avoid pricing pressures.
Geographic Expansion: Expanded operations in the U.S., Europe, and the Middle East to support aerospace and defense growth.
Global economic and geopolitical challenges: These challenges have led to restraint in CapEx spending by customers, impacting the company's revenue and growth potential.
Cost reduction and R&D balance: The need to reduce costs while maintaining continuity in key R&D programs poses a challenge to long-term growth and value creation.
Macroeconomic headwinds: The additive manufacturing industry faced strong macroeconomic headwinds in 2025, leading to a decline in year-over-year revenue.
Industrial printer and materials demand: Softness in demand for industrial printers and materials negatively impacted revenue.
Product mix and sales volume: Lower sales volume and less favorable product mix contributed to a decline in gross margins.
Regulatory and geopolitical risks in defense: Provisions in the National Defense Authorization Act (NDAA) restrict foreign-sourced 3D printing systems for Department of Defense programs, creating potential compliance and operational challenges.
Exposure to pricing pressure: The company has limited exposure to lower-end applications like jigs and fixtures, which are expected to face increased pricing pressure from non-U.S. suppliers.
Revenue concentration in priority markets: The company's growth is heavily reliant on priority markets like aerospace, defense, and healthcare, which could pose risks if these markets underperform.
Debt and financial stability: Although the company reduced its debt, it still faces financial challenges, including a negative adjusted EBITDA for 2025.
Revenue Expectations: The company expects revenue for the first quarter of 2026 to be in the range of $91 million to $94 million.
Adjusted EBITDA: Adjusted EBITDA for the first quarter of 2026 is expected to be within the range of a loss of $5 million to a loss of $3 million.
Aerospace and Defense Growth: The company anticipates over 20% growth in the aerospace and defense segment for 2026.
Dental Business Expansion: The company expects the dental business to become one of the largest revenue streams in the years ahead, driven by the adoption of 3D-printed dentures and a global annual recurring revenue opportunity of over $400 million for materials alone.
Personalized Health Services (PHS) Growth: The company expects continued growth in PHS in 2026 and beyond, driven by new applications, shortened response times, and FDA clearance for VSP solutions for skeletally mature adolescents.
Cost Savings Initiatives: The company plans to complete cost savings initiatives by the first half of 2026, aligning with 2026 priorities to focus on growth and profitability.
Facility Expansion: The company is expanding its U.S. facility in Littleton, Colorado, adding up to 80,000 square feet to support growth in aerospace and defense and healthcare markets.
Market Trends: The company expects increased demand for secure U.S.-based manufacturing for national security and space applications, driven by provisions in the National Defense Authorization Act (NDAA).
The selected topic was not discussed during the call.
The earnings call presents a mixed picture: while there's sequential revenue growth and positive developments in sectors like aerospace and defense, the overall year-over-year revenue declined by 9%. The company improved its EBITDA and reduced operating expenses, but gross margins were negatively impacted by a less favorable product mix. The Q&A revealed cautious guidance and some uncertainty, especially around consumer segments. Given these factors, the stock price is likely to remain stable with minor fluctuations, resulting in a neutral sentiment.
The earnings call reflects a negative sentiment due to a significant revenue decline, reduced gross margins, and a net loss. Despite some cost-cutting improvements and new partnerships, the lack of clear guidance on achieving breakeven and the unclear management responses in the Q&A section contribute to investor uncertainty. The positive developments in the dental market and new partnerships are overshadowed by the overall financial performance and market concerns, leading to a likely negative stock price reaction.
The earnings call presents a mixed picture. The company's cost reduction and R&D investments are positive, but the withdrawal of 2025 guidance and uncertainty in capital spending are concerning. The dental market expansion, especially with the NextDent 300, shows promise, yet the aligner business decline and vague profitability timelines weigh negatively. The Q&A reveals cautious optimism, but management's unclear responses on some issues add uncertainty. Overall, the sentiment is neutral with no strong catalysts for a significant stock price move.
The earnings call highlights several challenges: declining revenues, reduced margins, and increased losses. The withdrawal of guidance and competitive pressures add to the negative sentiment. Although there are positive aspects, such as cash position improvement and shareholder return plans, the overall financial performance and market conditions suggest a negative outlook. The Q&A section reinforces these concerns, with management acknowledging inventory volatility and reassessing R&D efforts. The negative sentiment is further supported by the lack of guidance and cost-cutting measures, indicating market instability.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.